NVAX Novavax Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: NVAX
  4. Earnings
?
Relative Growth: Rel. Growth: 3
Relative Strength: Rel. Strength: 58
Relative Valuation: Rel. Valuation: 19
Relative Profitability: Rel. Profitability: 22

EPS in 2026 (TTM): -$0.54

Last Report Period Date: Mar 31, 2026

As of June 2026, according to Novavax's latest financial report, the company's current EPS (TTM) is -$0.54. Novavax's EPS for 2025 came in at $2.72, marking an increase from -$1.23 in 2024. Novavax's earnings per share for the quarterly report ending on Mar 31, 2026 was -$0.06.

NVAX earnings history

Historical annual and quarterly earnings per share (EPS) data for Novavax
EPS (TTM)
-$0.54
EPS Growth YoY (Quarterly)
-101.9%
EPS (Quarterly)
-$0.06
EPS Growth (Quarterly)
-154.5%

The annual EPS in 2025 was $2.72, an increase of 321.1% from -$1.23 in 2024. The quarterly EPS for the period ending Mar 31, 2026, was -$0.06, marking a 101.9% decrease from the same quarter last year. NVAX's TTM EPS stands at -$0.54 as of March 2026. Novavax's EPS for 2024 stood at -$1.23, a 77.3% increase from 2023.

NVAX earnings chart

NVAX EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-101.9%
EPS growth YoY
321.1%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Over the last 12 months, Novavax has registered an EPS growth of -101.9% (YoY, quarterly).

NVAX Earnings Waterfall

Breakdown of revenue, profit and net income for Novavax

NVAX Earnings vs Peers

What are the earnings of NVAX compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
AGEN Agenus Inc 1.85 100% N/A N/A
PFE Pfizer Inc 18.87 -3.5% -37.4% -3.7%
NVS Novartis AG 21.85 21.8% 31.2% 15.2%
AZN Astrazeneca plc 26.98 45.4% 46% 22%
SRPT Sarepta Therapeutics Inc 28.77 -388.7% N/A N/A
EBS Emergent BioSolutions Inc N/A 127.2% N/A -29.9%
BCRX Biocryst Pharmaceuticals Inc N/A 393% N/A N/A
NNVC Nanoviricides Inc N/A 10% N/A N/A
CLDX Celldex Therapeutics Inc N/A -59.2% N/A N/A
NVAX Novavax Inc N/A 321.1% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.